^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis
Excerpt:
In subgroup analysis, PBRM1 mutations were observed to be linked with improved OS (HR: 0.650, 95 %CI: 0.440–0.960, p = 0.030), PFS (HR: 0.539, 95 %CI: 0.314–0.926, p = 0.025) and TTF (HR: 0.490, 95 %CI: 0.271–0.885, p = 0.018) in RCC patients receiving ICIs.
DOI:
https://doi.org/10.1016/j.gene.2022.146638
